Utah Medical Products ROE 2006-2018 | UTMD
Current and historical return on equity (ROE) values for Utah Medical Products (UTMD) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Utah Medical Products ROE for the three months ending December 31, 2018 was 18.03%.
| Utah Medical Products ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2018-12-31 | $0.02B | $0.09B | 20.93% |
| 2018-09-30 | $0.01B | $0.09B | 14.41% |
| 2018-06-30 | $0.01B | $0.08B | 11.08% |
| 2018-03-31 | $0.01B | $0.08B | 11.29% |
| 2017-12-31 | $0.01B | $0.08B | 11.65% |
| 2017-09-30 | $0.02B | $0.08B | 20.00% |
| 2017-06-30 | $0.01B | $0.08B | 19.18% |
| 2017-03-31 | $0.01B | $0.07B | 18.18% |
| 2016-12-31 | $0.01B | $0.07B | 16.84% |
| 2016-09-30 | $0.01B | $0.07B | 16.78% |
| 2016-06-30 | $0.01B | $0.07B | 17.08% |
| 2016-03-31 | $0.01B | $0.07B | 17.27% |
| 2015-12-31 | $0.01B | $0.07B | 17.78% |
| 2015-09-30 | $0.01B | $0.07B | 18.11% |
| 2015-06-30 | $0.01B | $0.07B | 18.39% |
| 2015-03-31 | $0.01B | $0.06B | 18.60% |
| 2014-12-31 | $0.01B | $0.07B | 18.68% |
| 2014-09-30 | $0.01B | $0.06B | 18.97% |
| 2014-06-30 | $0.01B | $0.07B | 19.51% |
| 2014-03-31 | $0.01B | $0.06B | 20.51% |
| 2013-12-31 | $0.01B | $0.06B | 21.62% |
| 2013-09-30 | $0.01B | $0.06B | 20.75% |
| 2013-06-30 | $0.01B | $0.05B | 21.57% |
| 2013-03-31 | $0.01B | $0.05B | 20.30% |
| 2012-12-31 | $0.01B | $0.05B | 20.94% |
| 2012-09-30 | $0.01B | $0.05B | 22.10% |
| 2012-06-30 | $0.01B | $0.05B | 20.93% |
| 2012-03-31 | $0.01B | $0.05B | 21.69% |
| 2011-12-31 | $0.01B | $0.04B | 17.61% |
| 2011-09-30 | $0.01B | $0.04B | 17.95% |
| 2011-06-30 | $0.01B | $0.04B | 17.95% |
| 2011-03-31 | $0.01B | $0.04B | 15.48% |
| 2010-12-31 | $0.01B | $0.04B | 17.95% |
| 2010-09-30 | $0.01B | $0.04B | 17.95% |
| 2010-06-30 | $0.01B | $0.04B | 18.30% |
| 2010-03-31 | $0.01B | $0.04B | 21.33% |
| 2009-12-31 | $0.01B | $0.04B | 21.92% |
| 2009-09-30 | $0.01B | $0.04B | 22.38% |
| 2009-06-30 | $0.01B | $0.04B | 21.92% |
| 2009-03-31 | $0.01B | $0.04B | 21.33% |
| 2008-12-31 | $0.01B | $0.04B | 20.78% |
| 2008-09-30 | $0.01B | $0.04B | 20.25% |
| 2008-06-30 | $0.01B | $0.04B | 20.51% |
| 2008-03-31 | $0.01B | $0.04B | 20.92% |
| 2007-12-31 | $0.01B | $0.04B | 21.19% |
| 2007-09-30 | $0.01B | $0.04B | 21.62% |
| 2007-06-30 | $0.01B | $0.04B | 22.07% |
| 2007-03-31 | $0.01B | $0.04B | 22.54% |
| 2006-12-31 | $0.01B | $0.04B | 23.02% |
| 2006-09-30 | $0.01B | $0.04B | 23.53% |
| 2006-06-30 | $0.01B | $0.03B | 23.70% |
| 2006-03-31 | $0.01B | $0.03B | 23.70% |
| 2005-12-31 | $0.01B | $0.03B | 23.36% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.321B | $0.042B |
| Utah Medical Products is in the business of producing cost-effective devices for the healthcare industry which are predominantly proprietary, disposable and for hospital use. The company's success in rapidly producing solutions comes from its proven ability to integrate a number of engineering and technical disciplines in electronics, software, mechanical packaging, instrumentation, optics and materials. The resulting proprietary products represent significant incremental improvementsover existing clinical techniques. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $129.838B | 25.32 |
| Medtronic (MDT) | Ireland | $112.952B | 16.51 |
| Stryker (SYK) | United States | $67.256B | 24.66 |
| Boston Scientific (BSX) | United States | $48.820B | 23.72 |
| Baxter (BAX) | United States | $37.991B | 24.37 |
| Zimmer Biomet Holdings (ZBH) | United States | $24.550B | 15.71 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $16.615B | 0.00 |
| Canopy Growth (CGC) | Canada | $14.912B | 0.00 |
| ResMed (RMD) | United States | $14.218B | 26.96 |
| Aurora Cannabis (ACB) | Canada | $9.118B | 64.29 |
| Bio-Rad Laboratories (BIO) | United States | $8.765B | 50.28 |
| Perrigo (PRGO) | Ireland | $6.633B | 10.75 |
| Hill-Rom Holdings (HRC) | United States | $6.374B | 19.72 |
| Insulet (PODD) | United States | $4.900B | 1642.60 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.701B | 0.00 |
| ICU Medical (ICUI) | United States | $4.568B | 28.29 |
| Haemonetics (HAE) | United States | $4.189B | 37.16 |
| Hutchison China MediTech (HCM) | China | $4.046B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $3.268B | 0.00 |
| Neogen (NEOG) | United States | $2.958B | 48.10 |
| NuVasive (NUVA) | United States | $2.784B | 24.18 |
| Quidel (QDEL) | United States | $2.365B | 21.17 |
| National Vision Holdings (EYE) | United States | $2.220B | 43.66 |
| Aphria (APHA) | $1.917B | 0.00 | |
| HEXO (HEXO) | $1.424B | 0.00 | |
| Phibro Animal Health (PAHC) | United States | $1.349B | 19.38 |
| VAREX IMAGING (VREX) | United States | $1.222B | 23.93 |
| Cardiovascular Systems (CSII) | United States | $1.190B | 854.00 |
| AtriCure (ATRC) | United States | $1.049B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.931B | 25.16 |
| Omeros (OMER) | United States | $0.908B | 0.00 |
| PetIQ (PETQ) | United States | $0.862B | 24.67 |
| MacroGenics (MGNX) | United States | $0.791B | 0.00 |
| Cerus (CERS) | United States | $0.787B | 0.00 |
| NanoString Technologies (NSTG) | United States | $0.737B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.689B | 0.00 |
| Evolus (EOLS) | United States | $0.681B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.666B | 22.66 |
| OraSure Technologies (OSUR) | United States | $0.594B | 25.86 |
| Surmodics (SRDX) | United States | $0.546B | 79.43 |
| LeMaitre Vascular (LMAT) | United States | $0.536B | 25.46 |
| Meridian Bioscience (VIVO) | United States | $0.531B | 15.82 |
| Quanterix (QTRX) | United States | $0.492B | 0.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.322B | 0.00 |
| Insys Therapeutics (INSY) | United States | $0.313B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.305B | 125.85 |
| Vapotherm (VAPO) | United States | $0.296B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.271B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.219B | 0.00 |
| Owens & Minor (OMI) | United States | $0.213B | 2.91 |
| Zynex (ZYXI) | United States | $0.171B | 18.31 |
| Chimerix (CMRX) | United States | $0.133B | 0.00 |
| Bovie Medical (APYX) | United States | $0.131B | 0.00 |
| Fonar (FONR) | United States | $0.125B | 6.68 |
| Chembio Diagnostics (CEMI) | United States | $0.121B | 0.00 |
| Surface Oncology (SURF) | United States | $0.113B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.090B | 0.00 |
| Female Health (VERU) | United States | $0.088B | 0.00 |
| United-Guardian (UG) | United States | $0.088B | 20.06 |
| CAS Medical Systems (CASM) | United States | $0.072B | 0.00 |
| Neurotrope (NTRP) | United States | $0.071B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.071B | 21.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.070B | 0.00 |
| ImmuCell (ICCC) | United States | $0.043B | 0.00 |
| Senestech (SNES) | United States | $0.034B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.031B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.025B | 0.00 |
| Myomo (MYO) | United States | $0.021B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.018B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 13.71 |
